Market Research Report
Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
|Published by||BCC Research||Product code||294447|
|Published||Content info||302 Pages
Delivery time: 1-2 business days
|Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets|
|Published: April 12, 2018||Content info: 302 Pages||
The global market for circulating tumor cell technology will grow from nearly $4.6 billion in 2017 to around $10.3 billion by 2022 with a compound annual growth rate (CAGR) of 17.6% for the period of 2017-2022.
The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment, currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area are included to support the clinical testing market.
The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies.
The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.
Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.